TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7817807

Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol for 2 years
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy age-matched males (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol for 1 year
Number of subjects: 30
Study: 3287881

Group type: EXPERIMENTAL
Intervention: Diltiazem (10-mg intravenous bolus followed by 15 mg/hr intravenous infusion during 72 hours, followed by 4 X 60 mg during 21 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30040757

Group type: EXPERIMENTAL
Intervention: Flow group (video game task inducing flow)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (video game task not inducing flow)
Number of subjects: 20
Study: 28029710

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (CONNECT)
Number of subjects: 0
Study: 24914489

Group type: EXPERIMENTAL
Intervention: Booster sessions with cognitive techniques
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard cognitive-behavioral group therapy (CBGT)
Number of subjects: 44
Study: 22804715

Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 21908466

Group type: EXPERIMENTAL
Intervention: Tablets moistened with 3 ml of normal saline
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tablets moistened with 3 ml of 5% acetic acid
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dry tablets
Number of subjects: 42
Study: 18288734

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mononuclear bone marrow cells (MBMC)
Number of subjects: 26
Study: 16921039

Group type: EXPERIMENTAL
Intervention: Cisplatin plus BCNU plus SRT (Arm C)
Number of subjects: 401

Group type: COMPARATOR
Intervention: BCNU plus SRT (Arm A)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Cisplatin plus BCNU plus ART (Arm D)
Number of subjects: 401

Group type: COMPARATOR
Intervention: BCNU plus ART (Arm B)
Number of subjects: 401

Group type: COMPARATOR
Intervention: BCNU plus RT (Arms A and B)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Cisplatin, BCNU, and RT (Arms C and D)
Number of subjects: 401
Study: 12588472

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg b.i.d.
Number of subjects: 3118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3118
Study: 11119395

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d
Number of subjects: 2561

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Cervical smears
Number of subjects: 2561
Study: 8936545

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 1 mg.kg‐1 without fentanyl
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam 0.4 mg.kg‐1 without fentanyl
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 1 mg.kg‐1 with fentanyl 0.75 microgram.kg‐1 i.v.
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam 0.4 mg.kg‐1 with fentanyl 0.75 microgram.kg‐1 i.v.
Number of subjects: 127
Study: 1556041

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Meprobamate
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 29438373

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg per day, per os; days 1-14; 21 days per cycle)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 28865466

Group type: EXPERIMENTAL
Intervention: Supportive supervision intervention
Number of subjects: 0
Study: 25706092

Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/r, dasabuvir, and ribavirin for 12 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/r, dasabuvir, and ribavirin for 24 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/r, dasabuvir, and ribavirin
Number of subjects: 63
Study: 23563195

Group type: EXPERIMENTAL
Intervention: Automated tube voltage selection and automated tube current modulation (protocol A)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Automated tube current modulation alone (protocol B)
Number of subjects: 3
Study: 21501950

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation
Number of subjects: 702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study: 19362282

Group type: EXPERIMENTAL
Intervention: Slit mesh technique (S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonslit mesh technique (NS)
Number of subjects: 40
Study: 16702370

Group type: EXPERIMENTAL
Intervention: Daily cigarette smoking
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Atypical cells of unknown significance or squamous intraepithelial lesion
Number of subjects: 205
Study: 15353389

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-1.5 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Haloperidol (0.5-1.5 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 120
Study: 11322352

Group type: EXPERIMENTAL
Intervention: Resistive heating
Number of subjects: 100

Group type: COMPARATOR
Intervention: Passive warming
Number of subjects: 100
Study: 7966039

Group type: EXPERIMENTAL
Intervention: CA-125 levels in peritoneal fluid
Number of subjects: 46

Group type: COMPARATOR
Intervention: Serum CA-125 levels
Number of subjects: 46
Study: 3119647

Group type: EXPERIMENTAL
Intervention: hCG/hMG treatment (2500 IU hCG twice a week + 150 IU hMG three times a week for 13 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (NaCl only, same injection schedule)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: hCG/hMG treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (NaCl only)
Number of subjects: 39
Study: 31801446

Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver for 1 hour
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study: 30153820

Group type: EXPERIMENTAL
Intervention: Vouchers for fruits and vegetables (FV) over a 1 year period
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no vouchers)
Number of subjects: 92
Study: 27926631

Group type: EXPERIMENTAL
Intervention: Percutaneous electrostimulation of the pectoral muscle combined with specific training (group 1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Specific training alone (group 2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No specific treatment (group 3)
Number of subjects: 75
Study: 24084630

Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer (VFR) in the maxilla and a cuspid retainer in the mandible (group V-CTC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: VFR in the maxilla combined with stripping of the incisors and cuspids in the mandible (group V-S)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Prefabricated positioner (group P)
Number of subjects: 75
Study: 22016099

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5145
Study: 20526206

Group type: EXPERIMENTAL
Intervention: BI 2536 (200 mg on day 1)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BI 2536 (50 or 60 mg on days 1 to 3)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (historical placebo)
Number of subjects: 95
Study: 18468955

Group type: EXPERIMENTAL
Intervention: 6000 mg chloride potassium dissolved in grape juice for 28 consecutive days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 16177196

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg calcium as carbonate, 3 times/d with meals)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo capsules identical in appearance
Number of subjects: 152
Study: 12668521

Group type: COMPARATOR
Intervention: Mutation-positive patients with Fabry disease
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with LVH
Number of subjects: 30
Study: 10047688

Group type: EXPERIMENTAL
Intervention: Chinese Hamster Ovary cell drived HB vaccine (CDV)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Plasma drived HB vaccine (PDV)
Number of subjects: 225
Study: 8721550

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: High-dose ganciclovir
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Combination foscarnet and ganciclovir
Number of subjects: 279
Study: 1839125

Group type: EXPERIMENTAL
Intervention: Isradipine (0.4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nifedipine (2.0 mg)
Number of subjects: 12
Study: 6344896

Group type: EXPERIMENTAL
Intervention: Tienilic acid (mean daily dose 278 mg, range 125-500 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional diuretics (mainly thiazide)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional diuretics
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tienilic acid and Conventional diuretics
Number of subjects: 96
Study: 29300253

Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy plus dermal allograft
Number of subjects: 114

Group type: COMPARATOR
Intervention: Anterior colporrhaphy alone
Number of subjects: 114
Study: 27841850

Group type: EXPERIMENTAL
Intervention: Dermacyn
Number of subjects: 110

Group type: COMPARATOR
Intervention: Metronidazole physiological saline
Number of subjects: 110
Study: 26554360

Group type: EXPERIMENTAL
Intervention: High-dose target-controlled naloxone infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study: 22733244

Group type: EXPERIMENTAL
Intervention: Partial removable dental prosthesis (PRDP) retained with precision attachments
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Shortened dental arch (SDA) concept preserving or restoring a premolar occlusion
Number of subjects: 152
Study: 21735946

Group type: EXPERIMENTAL
Intervention: Educational leaflet
Number of subjects: 533

Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 533
Study: 19302911

Group type: EXPERIMENTAL
Intervention: Test formulation of anagrelide (2 mg/d, taken as 4 capsules)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Reference formulation of anagrelide
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Test formulation of anagrelide
Number of subjects: 34
Study: 17553466

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 IU
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 23
Study: 12622306

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 0
Study: 10832808

Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg/day)
Number of subjects: 17
Study: 9322290

Group type: EXPERIMENTAL
Intervention: DTP+Pedvax HIB
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: DTP-PRP-T
Number of subjects: 271

Group type: COMPARATOR
Intervention: DTP
Number of subjects: 271
Study: 8342236

Group type: EXPERIMENTAL
Intervention: In-person recruitment strategy (standard)
Number of subjects: 852

Group type: COMPARATOR
Intervention: By-mail recruitment strategy
Number of subjects: 852
Study: 2944268

Group type: EXPERIMENTAL
Intervention: Cyproteronacetate (AndrocurR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower dose cyproteronacetate plus lisuride (DoperginR)
Number of subjects: 0
Study: 31230494

Group type: EXPERIMENTAL
Intervention: Direct release Mg2+ supplement (one phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed release Mg2+ supplement (two phases)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both test products
Number of subjects: 0
Study: 30684328

Group type: EXPERIMENTAL
Intervention: Kinesitherapy for more than four days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Kinesitherapy for less than four days
Number of subjects: 40
Study: 27504003

Group type: EXPERIMENTAL
Intervention: Preventive PCI
Number of subjects: 219

Group type: COMPARATOR
Intervention: Culprit-artery-only PCI
Number of subjects: 219
Study: 24526745

Group type: EXPERIMENTAL
Intervention: Structured intervention with written instructions (SIW)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Structured intervention with follow‐up visits (SIF)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 532
Study: 22313729

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 180
Study: 20377925

Group type: EXPERIMENTAL
Intervention: Wagyu beef (100 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Kangaroo meat (100 g)
Number of subjects: 10
Study: 18360139

Group type: EXPERIMENTAL
Intervention: Family-Maintained Progress Journal
Number of subjects: 91

Group type: COMPARATOR
Intervention: Usual information (Control)
Number of subjects: 91
Study: 16473224

Group type: EXPERIMENTAL
Intervention: AcrySof Natural IOL
Number of subjects: 297

Group type: COMPARATOR
Intervention: AcrySof single-piece IOL
Number of subjects: 297
Study: 12050252

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily for 2 years
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 11148939

Group type: EXPERIMENTAL
Intervention: Standardized, nonpunitive medication‐use variance process
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional, multitiered incident‐reporting system for medication errors
Number of subjects: 0
Study: 9289431

Group type: EXPERIMENTAL
Intervention: Surgical treatment of ovarian neoplasms
Number of subjects: 40
Study: 1917410

Group type: EXPERIMENTAL
Intervention: Iopamidol 370
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iohexol 350
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ioxaglate 320
Number of subjects: 40
Study: 6120389

Group type: EXPERIMENTAL
Intervention: Low dose oral prednisolone with azathioprine
Number of subjects: 72

Group type: COMPARATOR
Intervention: High dose oral prednisolone with azathioprine
Number of subjects: 72
Study: 31296648

Group type: EXPERIMENTAL
Intervention: Group Maintenance (GM)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Self-Directed Maintenance (SM)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 301
Study: 28317511

Group type: EXPERIMENTAL
Intervention: Quarterly assessed arm (structured interviews, breath alcohol analysis tests, and blood draws conducted quarterly)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Minimally assessed arm (engaged in procedures only once, at 6 months after baseline)
Number of subjects: 314
Study: 26387030

Group type: EXPERIMENTAL
Intervention: Milrinone-Esmolol (ME)
Number of subjects: 90
Study: 24431462

Group type: COMPARATOR
Intervention: C allele carriers (nonrisk‐associated)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Healthy controls and siblings (C > T/T)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Patients (T/T > C)
Number of subjects: 611
Study: 22340989

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous dexamethasone and local betamethasone injected at the tongue base
Number of subjects: 30
Study: 23440680

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.025-0.3 g/kg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17687131

Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 3306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3306

Group type: EXPERIMENTAL
Intervention: NXY-059 (among patients treated with alteplase)
Number of subjects: 3306

Group type: COMPARATOR
Intervention: Placebo (among patients treated with alteplase)
Number of subjects: 3306
Study: 16291413

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg QD for 10 days during the second cycle
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12479423

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with a 3 ml h(‐1) continuous infusion of fentanyl (2 microg) and bupivacaine (0.125%) for the first 3 days, with patient-controlled analgesia allowing an additional 5 ml of the same solution when pain score > 4.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Not applicable (control group with no epidural analgesia).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine (0.125%) after 3 days.
Number of subjects: 20
Study: 9661553

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sciatic-femoral nerve block
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham nerve block
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (femoral and sciatic)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks
Number of subjects: 36
Study: 7629581

Group type: EXPERIMENTAL
Intervention: Protocol 1: infusion of 201Tl (111 MBq), insulin (5 U), potassium (10 mEq) in 10% glucose solution (250 ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Protocol 2: infusion of 201Tl (111 MBq), potassium (10 mEq), insulin (5 U) in 5% glucose (250 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control: stress and 3-hr reinjection images (Protocol 1)
Number of subjects: 30
Study: 2199721

Group type: EXPERIMENTAL
Intervention: Isoptin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obsidian
Number of subjects: 0
Study: 7033847

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice daily for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31262846

Group type: EXPERIMENTAL
Intervention: Video Consultations (VC)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Face-to-Face Consultations (FTFC)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Telephone Consultations (TC)
Number of subjects: 149
Study: 27749966

Group type: EXPERIMENTAL
Intervention: Manualised program for early-onset conduct problems
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (30 families)
Number of subjects: 58
Study: 26082085

Group type: EXPERIMENTAL
Intervention: Alginate-hydrogel in combination with standard medical therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard medical therapy alone (Control)
Number of subjects: 78
Study: 23883807

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) nasal spray at 110 μg once daily for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 33
Study: 21506020

Group type: EXPERIMENTAL
Intervention: Credit and family planning services provided together
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Only credit services provided
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Only family planning services provided
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no services provided)
Number of subjects: 0
Study: 19297788

Group type: EXPERIMENTAL
Intervention: Alendronate (bisphosphonate), once-weekly treatment for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment, once-weekly for 6 months
Number of subjects: 60
Study: 17678456

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 509

Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 509
Study: 17194255

Group type: COMPARATOR
Intervention: Placebo (PLA; 34 g dextrose)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Beta-alanine (b‐Ala; 1.6 g b‐Ala plus 34 g dextrose)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM; 5.25 g CrM plus 34 g dextrose)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Beta-alanine plus creatine (CrBA; 5.25 g CrM plus 1.6 g b‐Ala plus 34 g dextrose)
Number of subjects: 51
Study: 12692611

Group type: EXPERIMENTAL
Intervention: Calcium phosphate mouth rinse (Caphosol) with fluoride treatments
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard regimen of fluoride rinsing and placebo tray treatments
Number of subjects: 95
Study: 10584132

Group type: EXPERIMENTAL
Intervention: 200 mg/m2 amifostine i.v., 30 minutes before radiation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 26
Study: 8914871

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve after angioplasty
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve at predischarge
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve at follow-up
Number of subjects: 14

Group type: COMPARATOR
Intervention: Coronary flow reserve in infarct patients vs reference patients
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Infarct region wall motion after angioplasty
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Infarct region wall motion at predischarge
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Infarct region wall motion at follow-up
Number of subjects: 14
Study: 1877263

Group type: EXPERIMENTAL
Intervention: sucralfate 2 g q12h for five doses with ciprofloxacin 750 mg concurrently (Treatment A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ciprofloxacin 750 mg administered two hours before the fifth dose of sucralfate (Treatment B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ciprofloxacin 750 mg six hours before the fifth dose of sucralfate (Treatment C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: ciprofloxacin 750 mg alone (Treatment D)
Number of subjects: 12
Study: 6311789

Group type: EXPERIMENTAL
Intervention: Ceftazidime (single dose preoperatively)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cefotaxime (three doses perioperatively)
Number of subjects: 68
Study: 29481976

Group type: EXPERIMENTAL
Intervention: Online ACT + TAU
Number of subjects: 67
Study: 26320001

Group type: EXPERIMENTAL
Intervention: Happy Science doctrine‐based group psychotherapy (n = 58), 5 sessions of 90 minutes each at one-week intervals
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care including medication (n = 60)
Number of subjects: 118
Study: 26571315

Group type: EXPERIMENTAL
Intervention: 20G biopsy needle
Number of subjects: 122

Group type: COMPARATOR
Intervention: 18G biopsy needle
Number of subjects: 122